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Abstract 
Purpose: To study the effect of Alisma plantago-aquatica Linn. extract (APLE) on chronic prostatitis in 
rats. 
Methods: Experimental chronic non-bacterial prostatitis (CNP) was induced in rats by injecting 
carrageenan into prostate. Rats in drug-treated groups were administered APLE or cernilton (positive 
control, i.e., reference standard) for 3 weeks while rats in normal and negative control groups were 
treated with saline at the same time. After treatment, prostate index (PI) and prostate-specific antigen 
(PSA) of all the rats were examined by enzyme-linked immunosorbent assay (ELISA). In addition, the 
relative inflammatory factors, tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), cyclooxygenase-2 
(COX-2), prostaglandin E2 (PEG2), transforming growth factor-β1 (TGF-β1) and connective tissue 
growth factor (CTGF) of the prostate tissues were measured by ELISA.  
Results: A high dose of APLE (480 mg/kg) significantly decreased PI (0.7 ± 0.2 mg/g) relative to 
reference group (2.8 ± 0.3 mg/g, p < 0.01), and significantly decreased PSA level (128.6 ± 12.3 pg/mL) 
relative to reference group (321.3 ± 16.4 pg/mL, p < 0.01). Compared with reference group, TNF-α level 
(109.7 ± 9.3 pg/mL, p < 0.01), IL-1β level (98.3 ± 12.5 pg/mL, p < 0.01), PEG2 level (81.5 ± 4.2 pg/mL, 
p < 0.01), COX-2 level (10.5 ± 2.6 pg/mL, p < 0.01), TGF-β1 level (86.8 ± 7.3 pg/mL, p < 0.01) and 
CTGF level (70.3 ± 4.3 pg/mL, p < 0.01) of prostate tissues of high-dose APLE group rats decreased 
significantly.  
Conclusion: APLE shows significant anti-chronic prostatitis activity in rats. Further studies are, 
however, required to ascertain its therapeutic potentials in humans 
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Chronic prostatitis is characterized by a variety of 
symptoms, and has been shown to have a 
significant impact on quality of life [1,2]. While 
most typically associated with pain in the pelvic 
region, patients may have varying degrees of 
obstructive and/or irritating voiding symptoms, 
pain with ejaculation, sexual dysfunction, 
depression and/or psychosocial dysfunction that 
may be concomitant or related to the other 
symptoms. Chronic pelvic or genitourinary pain is 
a primary component of the condition and is 
typically present for at least three of the 
preceding 6 months [3]. As much as 10 – 15 % of 
the male population may be affected at some 
point in their lives, and affects men of all ages. 
Prostatitis is responsible for up to 2 million 
outpatient clinic visits per year, including 8 % of 
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all male visits to a urologist and 1 % of men 
presenting to primary care physicians [4]. 
Cernilton is one of the most widely used drugs 
for treating chronic non-bacterial prostatitis, but 
has not achieved significant curative effect in 
clinic. 
 
At present, orthodox treatment of chronic 
prostatitis is not satisfactory, and a large number 
of patients are opting for therapy of traditional 
Chinese medicine. Herbal-based therapies are 
prevalent and popular in urological disease, more 
so in prostatic disorders. Examples include 
Chinese herbs, green tea extracts, saw palmetto 
and bee pollen, but unfortunately not all studies 
are adequately controlled [5-7]. 
 
The plant Alisma plantago-aquatica Linn., which 
is widely distributed in Southwest of China, is the 
main material of traditional Chinese medicine 
‘‘Zexie’’. It was used as folk medicine for 
immune-modulation [8], anti-tumor [9] and anti-
bacterial [10,11]. The aim of the present study 
was to evaluate the therapeutic effects of APLE 
against carrageenan-induced chronic non-
bacterial prostatitis as well as explore its possible 






Samples of Alisma plantago-aquatica Linn. were 
collected from Liuzhou City, Guangxi Province in 
China in May 2016. Taxonomic identification of 
the plant was performed by Professor Ping Wang 
of Tianjin Medical University, in China. A voucher 
specimen (no. APLE 201605002) was deposited 
in the herbarium of College of Pharmacy, Tianjin 
Medical University, China for future reference. 
  
Alisma plantago-aquatica Linn was dried in an 
oven. APLE was obtained by steeping the dried 
Alisma plantago-aquatica Linn. in water at 60 oC 
three times, each for 1 h before first drying in a 
oven and then freeze-drying the last extract thus 
obtained. One gram powder was equivalent to 





Eight weeks old male Wistar rats (220 – 250 g) 
were provided by the Experimental Animal 
Center of Tianjin Municipality (Certificate no. 
SYXK 2002-0006). The animals had free access 
to feed and water, and were allowed to 
acclimatize for at least one week before use. The 
rat experiment was approved by the Animal Care 
and Use Committee of Tianjin Medical University 
(approval ref no. 20100405) and was carried out 
in compliance with the Directive 2010/63/EU on 
the handling of animals used for scientific 
purposes [12]. 
 
Animal groups  
 
The rats were randomly divided into six groups of 
ten rats in each: control group, reference group, 
positive drug group (cernilton 100 mg/kg) as well 
as APLE groups, namely, 120, 240 and 480 
mg/kg doses. The drugs were dissolved in water, 
and administered using a 5 mL syringe with a 4-
cm long gavage needle through the mouth once 
daily for 3 weeks.  
 
Carrageenan-induced chronic non-bacterial 
prostatitis model (CNP) 
 
Chronic non-bacterial prostatitis were induced as 
previously described [13].  Prostates of rats in 
control group were injected with 0.1 mL saline by 
an injector, and the same volume of 1 % 
carrageenan in rats of other groups. Seven days 
after preparing the model rats of chronic non-
bacterial prostatitis, rats in APLE group, they 
were orally administered APLE, while rats in 
positive (reference standard) group were 
administered cernilton, both groups for 3 weeks. 
Rats of normal and negative control groups were 
administered saline at the same time.  
 
Measurement of prostatic index (PI) and 
prostate specific antigen (PSA)  
 
The prostatic index (PI) of all rats was assessed 
as the ratio of prostate weight (mg) to rat body 
weight (g). A blood sample was taken from eye 
enucleation, and serum was separated at 3500 
r/min for 15 min and used for determination of 
prostate specific antigen (PSA) by ELISA kits 
(Nanjing Jiancheng Biological Technology Co 
Ltd, Najing, China). 
 
Biochemical assays  
 
After the rats were sacrificed by cervical 
dislocation, the pro-inflammatorycytokines TNF-α 
and IL-1β of prostate tissues of all rats were 
measured by commercial ELISA assay kits 
(Nanjing Jiancheng Biological Technology Co 
Ltd, Najing, China), according to manufacturer’s 
instruction. The samples and standards were all 
run in duplicates and the data were then 
averaged. The results were expressed as pg/mL. 
 
PGE2, COX-2, TGF-β1 and CTGF were 
measured in prostate tissues using commercial 
ELISA kits (Shenzhen Xin-Bo-Sheng Biological 
Technology Co Ltd, China). All assays were 
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performed in 10% prostate supernatant in 
accordance with manufacturer’s instructions. The 
levels of PGE2, COX-2, TGF-β1 and CTGF in 




Data are presented as mean ± standard 
deviation (SD) and were analyzed statistically by 
one-way ANOVA followed by Tukey’s multiple 
comparison using SPSS 16.0 software for 
Windows. Differences were considered 




Effect of APLE on PI and PSA 
 
The effects of oral administration of APLE on the 
levels of PI and PSA are summarized in Table 1. 
Compared with control group, PI and PSA level 
of reference group rats both increased 
significantly (p < 0.01). Compared with reference 
group, PI and PSA levels of high-dose of APLE 
decreased significantly (p < 0.01). 
 
Effect of APLE on TNF-α and IL-1β 
 
As shown in Table 2, TNF-α level was 88.6 
pg/mL in control group. Carrageenan-treatment 
caused significant increase in the level of TNF-α 
compared with the control group (p < 0.01). TNF-
α level decreased when treated with 480 mg/kg 
of APLE compared to control group (p < 0.01). 
The level of IL-1β was significantly increased in 
control group compared to control group (p < 
0.01). However, the IL-1β level was significantly 
decreased to 111.6 and 94.1 pg/mL at the dose 
of 240 and 480 mg/kg groups respectively (p < 
0.01). 
 
Effect of APLE on PGE2, COX-2, TGF-β1 and 
CTGF 
 
As shown in Table 3, the level of TGF-β1 was 
81.7 pg/mL in control group. Carrageenan 
caused significant increase in the level of TGF-
β1 in reference group (p < 0.01). After rats was 
treated with APLE for three weeks, the level of 
TGF-β1 was dose-dependently decreased (p < 
0.01). Similarly, the level of CTGF was elevated 
in model group when compared with the control 
group (p < 0.01). However, in APLE treated 
group, the elevation was suppressed compared 
with the reference group (p < 0.01).  
 
COX-2 level was increased significantly 
compared to control group (p < 0.01). However, 
treatment of APLE decreased the level of COX-2 
(p < 0.01). The level of PEG2 was increased in 
negative control group compared to control group 
(p < 0.01). Oral treatment of APLE at 240 and 
480 mg/kg resulted in significant decrease of 
PEG2 content when compared with negative 
control group (p < 0.01). 
 
Table 1: Effect of APLE on PI and PSA levels 
 
Group Dose (mg/kg)  PI (mg/g） PSA (pg/ml) 
Control — 0.7±0.2** 106.4±11.8** 
Negative control — 2.8±0.3 321.3±16.4 
Cernilton 100 1.6±0.4 141.7±13.5** 
APLE-L 120 1.7±0.3 268.5±28.3 
APLE-M 240 1.5±0.4* 159.2±17.5* 
APLE-H 480 0.8±0.3** 128.6±12.3** 
*P < 0.05，**p < 0.01 vs. negative control group; values are mean ± SD (n = 
10); APLE-L: low-dose of APLE; APLE-M: middle-dose of APLE; APLE-H: 
high-dose of APLE 
 
   Table 2: Effect of APLE on TNF-α and IL-1β levels 
 
Group Dose (mg/kg) TNF-α (pg/ml) IL-1β (pg/mL) 
Control — 88.6±7.7** 84.5±6.2** 
Negative control — 169.4±13.5 154.2±9.8 
Cernilton 100 128.3±9.5**  127.2±11.4** 
APLE-L 120 146.6±12.4 137.3±12.2 
APLE-M 240 134.1±9.3* 122.5±9.2** 
APLE-H 480 109.7±9.3** 98.3±12.5* 
*P < 0.05，**p < 0.01 vs. negative control group. Values are mean ± SD (n = 10) 
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         Table 3: Effect of APLE on PGE2, COX-2, TGF-β1 and CTGF levels 
 









Control  53.5±3.8** 12.3±1.8** 79.4±4.2** 71.6±4.5** 
Negative control  124.1±4.9 38.6±2.9 129.6±12.1 121.4±5.8 
Cernilton 100 76.3±4.2** 18.2±2.6* 115.3±8.7* 96.4±4.4** 
APLE-L 120 117.2±5.1* 22.3±4.7 123.6±8.4* 112.2±6.2 
APLE-M 240 90.2±5.4** 16.5±3.7** 111.4±7.2** 92.5±5.8** 
APLE-H 480 81.5±4.2** 10.5±2.6** 86.8±7.3** 70.3±4.3** 




Antibiotics are largely ineffective in the treatment 
of CNP as the chronic nature of the syndrome is 
thought not to be completely attributable to an 
ongoing active or latent bacterial infection. 
Despite this, up to almost 80 % of CNP patients 
receive antibiotics as treatment at some point 
during their disease course, more than 7 times 
that of non-CNP patients, and many receive 
multiple rounds of antibiotics despite lack of 
efficacy [14]. It is well accepted that the 
progression of CNP is related to the complex 
network of cytokines, including IL-1β and TNF-α 
[14,15]. IL-1β is a pro-inflammatory cytokine that 
induces the production of other inflammatory 
mediators involved in cellular recruitment, fever, 
acute phase protein release, increase of vascular 
permeability, and hyperalgesia [16]. TNF-α, a 
pleiotropic pro-inflammatory cytokine, is rapidly 
produced by macrophages in response to tissue 
damage [17]. Previous studies have shown that 
activation of transcription factor NF-κB by TNF-α 
is one of the myriad actions of TNF-α that cause 
genes to generate potentially cell damaging 
oxidative enzymes, as well as further release of 
TNF-α, IL-1β and other pro-inflammatory 
cytokines [18-20]. Cytokine based therapies have 
been found useful in preventing progression of 
chronic prostatitis [21]. 
 
In the present study, the levels of TNF-α and IL-
1β were increased in model group rats, whereas 
on treatment with APLE at 240 or 480 mg/kg, 
there was a significant decrease in the cytokine 
levels. APLE suppressed the release of pro-
inflammatory mediators due to its anti-
inflammatory activities. In this study, the levels of 
COX-2 and PEG2 in the model group, were 
enhanced. However, the increased levels of 
COX-2 and PEG2 were reversed in treatment 
group of APLE. In addition, it was found that 
APLE at the dose of 480 mg/kg significantly 
decreased COX-2 and PEG2 levels. Therefore, 
the anti-CNP effect of APLE may be related to its 
anti-inflammatory properties. 
 
TGF-β is the most extensively studied molecule   
in fibrosis and stimulates the production of 
reactive oxygen species (ROS) in various types 
of cells. Whereas ROS activates TGF-β and 
mediate many of the fibrogenic effects of TGF-β 
[22]. TGF-β1 is known to induce fibroblast 
differentiation into myofibroblast/smooth muscle 
cell in the human prostate [23]. In addition, other 
evidence suggests that pro-fibrotic effects of 
TGF-β may be partly mediated by CTGF [24]. As 
another potent profibrotic factor, CTGF is 
implicated in fibroblast proliferation, cellular 
adhesion, angiogenesis, and extracellular matrix 




The findings of this study reveal that APLE has 
anti-inflammatory activities and exerts anti-
chronic prostatitis effect in rats. However, further 
investigations are required determines its 
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